



Steven W. Chen, PharmD, FASHP, FCSHP, FNAP  
Associate Dean for Clinical Affairs  
chens@usc.edu



# Intent of this session

To share a **proven framework** for ensuring optimal results from medication therapy





## ***Questions to run on...***

- What medication-related problems do you have in your organization that remain unresolved?
- How can Comprehensive Medication Management be strategically implemented / expanded to deliver high value / ROI?







# Outline

- Quality and safety gaps in healthcare
- Comprehensive medication management (CMM)
  - Definition and comparison to MTM
  - Final results from USC CMMI HCIA
- CMM at local, state, and national levels
- Next steps

## Managed Care



# USC School of Pharmacy CMM Collaborations



## EXHIBIT ES-1. OVERALL RANKING

### COUNTRY RANKINGS

Top 2*
Middle
Bottom 2*

										
AUS	CAN	FRA	GER	NETH	NZ	NOR	SWE	SWIZ	UK	US

### OVERALL RANKING (2013)

#### Quality Care

Effective Care  
Safe Care  
Coordinated Care  
Patient-Centered Care

#### Access

Cost-Related Problem  
Timeliness of Care

#### Efficiency

#### Equity

#### Healthy Lives

**RANK THESE HEALTH CARE SYSTEMS ON OVERALL PERFORMANCE**

<b>Health Expenditures/Capita, 2011**</b>	<b>\$3,800</b>	<b>\$4,522</b>	<b>\$4,118</b>	<b>\$4,495</b>	<b>\$5,099</b>	<b>\$3,182</b>	<b>\$5,669</b>	<b>\$3,925</b>	<b>\$5,643</b>	<b>\$3,405</b>	<b>\$8,508</b>
---	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------	----------------

Notes: \* Includes ties. \*\* Expenditures shown in \$US PPP (purchasing power parity); Australian \$ data are from 2010.

Source: Calculated by The Commonwealth Fund based on 2011 International Health Policy Survey of Sicker Adults; 2012 International Health Policy Survey of Primary Care Physicians; 2013 International Health Policy Survey; Commonwealth Fund *National Scorecard 2011*; World Health Organization; and Organization for Economic Cooperation and Development, *OECD Health Data, 2013* (Paris: OECD, Nov. 2013).

[http://www.commonwealthfund.org/~media/files/publications/fund-report/2014/jun/1755\\_davis\\_mirror\\_mirror\\_2014.pdf](http://www.commonwealthfund.org/~media/files/publications/fund-report/2014/jun/1755_davis_mirror_mirror_2014.pdf)



**USC** University of  
Southern California

University of Southern California

DOC- CAN  
YOU SEE THE  
PROBLEM?

I'M AFRAID SO.

INSURANCE  
COMPANIES



**1 MILLION**

PEOPLE WHO WILL HAVE  
A HEART ATTACK OR DIE  
FROM CORONARY HEART  
DISEASE THIS YEAR




**16.5  
MILLION**

AMERICANS AGE 20 AND  
OLDER WHO ARE LIVING  
WITH CORONARY HEART  
DISEASE

**795,000**

PEOPLE WHO WILL  
HAVE A STROKE  
THIS YEAR



**356,000**

CARDIAC ARRESTS THAT  
OCCUR OUTSIDE A HOSPITAL  
EACH YEAR



# HARD NUMBERS

By AMERICAN HEART ASSOCIATION NEWS

A sampling of U.S. data from the  
American Heart Association's 2018  
heart disease and stroke statistics report.



**103 MILLION**

ADULTS WITH HIGH  
BLOOD PRESSURE



**6.5 MILLION**

AMERICANS AGE 20 AND  
OLDER WHO ARE LIVING  
WITH HEART FAILURE

**38 PERCENT**

RISE IN THE NUMBER OF HIGH  
BLOOD PRESSURE DEATHS  
BETWEEN 2005 AND 2015



**23 MILLION**

ADULTS WITH  
**TYPE 2  
DIABETES**

**15 PERCENT**

ADULTS WHO  
SMOKED IN  
2015



**56 MILLION**

PEOPLE 40 AND OLDER  
WHO ARE ELIGIBLE FOR  
CHOLESTEROL-LOWERING  
STATINS



**38 PERCENT**


ADULTS WHO  
WERE OBESE  
AS OF 2014



Source: "Heart Disease and Stroke Statistics-  
2018 Update: A Report from the American Heart Association," *Circulation* (numbers rounded)

Published Jan. 31, 2018


## Age-adjusted trends in hypertension and controlled hypertension among adults aged 18 and over: United States, 1999–2016







## Study of ~7,200 Patients with Blood Pressure Above Goal: **Therapeutic Inertia- No Medication Change When Indicated**



If medication intensified on ~ 20% of visits, BP control rates would increase from 46.2% to 65.9% in 1 year

# Medication-Related Problems in U.S.

- Adverse effects from medications ~ 4<sup>th</sup> leading cause of death in U.S. (FDA)
- 75% of hospital readmissions among seniors are avoidable, primarily through better use of medications (James J., Health Affairs 2013)
- ½ of prescription medications taken every year in the US are used improperly (CDC, 2013)
- \$528.4 billion in annual healthcare costs due to suboptimal use of medications for chronic diseases- 16% of total healthcare expenditures (Ann Pharmacotherapy, 2018)




# Outline

- Quality and safety gaps in healthcare
- Comprehensive medication management (CMM)
  - Definition and comparison to MTM

# Comprehensive Medication Management

*The Patient-Centered Primary Care Collaborative (PCPCC) Defines Comprehensive Medication Management (CMM)*



Integrating Comprehensive Medication Management to Optimize Patient Outcomes. *Resource Guide*

# Comprehensive Medication Management is a New Standard of Care

Ensures each patient's medications are individually assessed.

Assessment determines if medication is:

- appropriate for the patient
- effective for the medical condition
- safe given the comorbidities and other medications being taken
- able to be taken by the patient as intended

# Comprehensive Medication Management is Patient Centered

CMM includes:

- individualized care plans that *achieve the intended goals of therapy*
- appropriate follow-up to determine actual *patient outcomes*
- patient understands, agrees with, and actively participates in the *treatment regimen*

*CMM optimizes each patient's medication experience and clinical outcomes.*


# 10-Step CMM Process

1. **Identify patients** that have not achieved treatment goals
2. **Understand** the patient's personal medication experience/history and preferences /beliefs.
3. Identify **actual use patterns** of ALL "medications"
4. **Assess each medication** for appropriateness, effectiveness, safety (including drug interactions), and adherence
5. Identify all **medication-related problems** that prohibit disease control
6. Develop a step-by-step **care plan** to achieve optimal outcomes
7. Secure **patient engagement and buy-in** in collaboration with PCP
8. **Document** all steps and current clinical status
9. **Follow-up** with patients to continue interventions until clinical goals/outcomes are achieved
10. **Work collaboratively** with physicians other team members to ensure the provision of optimal patient-centered care

From: The Patient-Centered Primary Care Collaborative

Characteristic	MTM	CMM
Conduct a comprehensive medication therapy review to identify all medication-related problems	✓	✓
Confirm medication-related problems including assessment, point-of-care testing, medication-related labs	✓	✓
Assess ALL medications and medical conditions		✓
Develop individualized medication care plan to address medication-related problems and ensure attainment of treatment goals	✓	✓
Add, substitute, discontinue, or modify medication doses	✓	✓
Generate complete medication record	✓	✓
Document care delivered and communicate to health care team	✓	✓
Ensure care is coordinated with other health care providers	✓	✓
Provide follow-up care in accordance with treatment-related goals		✓
Requires collaborative practice agreement between pharmacist and physician		✓

# Modes of CMM Delivery



- 1. Medical Groups** (Pay for Performance, Chronic Disease Management)
  - Cedars-Sinai, Sharp, USC, UCLA
- 2. Integrated into Medical Homes**
  - VA, Kaiser, safety net clinics
- 3. Community Pharmacies**
  - Ralphs, Walgreens, independents
- 4. Video telehealth-** USC, VA Health System
- 5. Telephonic** (“low-hanging fruit”)
  - MEDCO, Kaiser Permanente, SinfoniaRx, Heritage ACO, USC

<http://www.pcpcc.net/files/medmanagepub.pdf>

[http://www.cdc.gov/dhdsr/programs/nhdsp\\_program/docs/pharmacist\\_guide.pdf](http://www.cdc.gov/dhdsr/programs/nhdsp_program/docs/pharmacist_guide.pdf)



# Outline

- Quality and safety gaps in healthcare
- Comprehensive medication management (CMM)
  - Definition and comparison to MTM
  - Final results from USC CMMI HCIA



# \$12 Million USC / AltaMed CMMI Project: Specific Aims




10 teams

Pharmacist + Resident +  
Clinical Pharmacy Technician



Telehealth clinical  
pharmacy



Resident and  
technician training  
for expansion


## UNIVERSITY OF SOUTHERN CALIFORNIA

National Conference on Best  
Practices and Collaborations to  
Improve Medication Safety and  
Healthcare Quality

**Feb 2014 & 2016**

## OUTCOME MEASURES

- ✓ Healthcare Quality
- ✓ Safety
- ✓ Total Cost / ROI
- ✓ Patient & provider satisfaction
- ✓ Patient access



Web-based pharmacist training  
and credentialing


# USC Patient Targeting and Management Strategy



High cost patients



Frequent and recent  
acute care utilizers



48 EHR-embedded triggers  
to detect high risk patients



MD referrals



**Comprehensive  
Medication  
Management**


# USC Patient Targeting and Management Strategy



High cost patients



Frequent and recent acute care utilizers



48 EHR-embedded triggers to detect high risk patients



MD referrals



**Comprehensive Medication Management**

Treatment Goal Reached?

No

Yes

Unstable

**Clinical pharmacy tech “check-ins” every 2 months**

- Enrolled 6,000 patients since Oct 2012
  - Predominantly Hispanic, non-elderly women
- 3/4<sup>ths</sup> have hypertension, 36% uncontrolled
- 2/3<sup>rds</sup> have diabetes, 60% uncontrolled
- Low-moderate rates of hospitalizations

# Control Group Selection



Propensity scoring to match CPS enrollees (treatments) to similar patients receiving care at non-treatment clinics (controls) in three steps:

- Wave 1 treatment patients
- PACE treatment patients from Wave 2
- Non-PACE treatment patients from Wave 2

Covariates used to model the propensity score:

- Demographics
- Health status
- Utilization
- Other

# Changes in Clinical Measures (% of Patients with **Uncontrolled** Disease)

Condition	% Uncontrolled			
	Managed Patients		Unmanaged Patients	
	Baseline	6 months	Baseline	6 months
High blood pressure (SBP/DBP)	100	39%	100	48%
Elevated cholesterol (LDL)	100	38%	100	52%
Elevated Blood Sugar (HgA1c)	100	34%	100	57%

Sample restricted to patients with *uncontrolled* condition at baseline.

**Unmanaged** patients received *usual care* from AltaMed primary care physicians.

Interpretation: Program reduced rates of uncontrolled blood sugar (diabetes) by 23 percentage points relative to the unmanaged group (**34% vs. 57%**).


# Summary of Difference-in-Differences Results for Utilization (Treatment – Control, Probit Analysis)

At 6 month follow-up:

Readmissions per year per patient	<b>-16%</b>
-----------------------------------	-------------


Readmissions per year per patient primarily attributed to medications	<b>-33%</b>
---	-------------

# Untreated (Cohort) Versus Treated Patients, Preliminary Findings, USC CMMI Program




# Medication-Related Problems Identified Through CMMI Clinical Pharmacy Program


67,169 problems among 5,775 patients (Avg 11.6 per patient)



# Top Actions Taken by Pharmacists to Resolve Medication-Related Problems (excluding education)



# Physician Satisfaction




The typical primary care physician needs 18 hours a day to provide standard care, which does not include anything beyond preventative and common chronic disease care



*Ann Fam Med. 2005 May; 3(3): 209–214*  
*Am J Public Health. 2003 April; 93(4): 635–641*

# Patient Satisfaction




# Value Proposition- Comprehensive Medication Management

*Integration of CMM for high-risk patients:*

- *Lowers total healthcare costs (↓hospitalizations / readmits)*
- *Improves healthcare quality measures (Pay for performance)*
- *Improves medication safety (priority for CMS, others)*
- *Improves provider access (PCMH measure, video telehealth) and satisfaction (less staff turnover)*
- *Improves patient satisfaction (retention)*
- *Saves lives!*

# Greatest Opportunity for Applying Advanced Care Initiatives such as CMM...



# Top 10 Potentially Preventable Readmissions

APR DRG Number	Medical APR DRG Description
194	Heart Failure
140	Chronic Obstructive Lung Disease
750	Schizophrenia
139	Other Pneumonia
751	Major Depressive Disorder
198	Angina Pectoris and Coronary Atherosclerosis
753	Bipolar Disorders
720	Septicemia and Disseminated Infection
460	Renal Failure
201	Cardia Arrhythmia and Conduction Disturbance

All Patients Refined Diagnosis Related Groups (**APR DRG**) is a classification system that classifies patients according to their reason of admission, severity of illness and risk of mortality



# Outline

- Quality and safety gaps in healthcare
- Comprehensive medication management (CMM)
  - Definition and comparison to MTM
  - Final results from USC CMMI HCIA
- CMM at local, state, and national levels



# USC Value-Based Partnerships




LOS ANGELES CHRISTIAN  
HEALTH CENTERS  
"SERVING ALL, WITH OPEN HEARTS"



A Public Entity  
Inland Empire Health Plan



BlueShield



Keck Medical  
Center of USC



# Business Case for Spread and Sustainment of Advanced Practice Pharmacist Programs

- **Cost savings / ROI:** Reduction in acute care utilization for high-risk populations (e.g., Whole Person Care)
- **Direct billing:** LA County Dept of Mental Health (85% of physician payment rate)
- **Gain sharing / P4P**
- **340B program**
- **Medicare Quality Payment Program:** <https://qpp.cms.gov/>
- **Traditional fee-for-service billing:** Incident-to +/- hospital fee or POC testing, diabetes self-management, chronic care management, care transitions, Annual Medicare Wellness visits

## ONLINE FIRST

# Effectiveness of a Barber-Based Intervention for Improving Hypertension Control in Black Men

## *The BARBER-1 Study: A Cluster Randomized Trial*

Ronald G. Victor, MD; Joseph E. Ravenell, MD, MS; Anne Freeman, MSPH; David Leonard, PhD; Deepa G. Bhat, ME; Moiz Shafiq, MD; Patricia Knowles; Joy S. Storm, BS; Emily Adhikari, BA; Kirsten Bibbins-Domingo, PhD, MD, MAS; Pamela G. Coxson, PhD; Mark J. Pletcher, MD, MPH; Peter Hannan, MStat; Robert W. Haley, MD

**Background:** Barbershop-based hypertension (HTN) outreach programs for black men are becoming increasingly common, but whether they are an effective approach for improving HTN control remains uncertain.

**Methods:** To evaluate whether a continuous high blood pressure (BP) monitoring and referral program conducted by barbers motivates male patrons with elevated BP to pursue physician follow-up, leading to improved HTN control, a cluster randomized trial (BARBER-1) of HTN control was conducted among black male patrons of 17 black-owned barbershops in Dallas County, Texas (March 2006–December 2008). Participants underwent 10-week baseline BP screening, and then study sites were randomized to a comparison group that received standard BP pamphlets (8 shops, 77 hypertensive patrons per shop) or an intervention group in which barbers continually offered BP checks with haircuts and promoted physician follow-up with sex-specific peer-based health messaging (9 shops, 75 hypertensive patrons per shop). After 10 months, follow-up data were obtained. The primary outcome measure was change in HTN control rate for each barbershop.


**Results:** The HTN control rate increased more in intervention barbershops than in comparison barbershops (absolute group difference, 8.8% [95% confidence interval (CI), 0.8%–16.9%]) ( $P=.04$ ); the intervention effect persisted after adjustment for covariates ( $P=.03$ ). A marginal intervention effect was found for systolic BP change (absolute group difference,  $-2.5$  mm Hg [95% CI,  $-5.3$  to  $0.3$  mm Hg]) ( $P=.08$ ).

**Conclusions:** The effect of BP screening on HTN control among black male barbershop patrons was improved when barbers were enabled to become health educators, monitor BP, and promote physician follow-up. Further research is warranted.

**Trial Registration:** [clinicaltrials.gov](http://clinicaltrials.gov) Identifier: NCT00325533

*Arch Intern Med.* 2011;171(4):342–350.  
Published online October 25, 2010.  
doi:10.1001/archinternmed.2010.390

# Kaiser Permanente team-based care model



# BARBER-2 Trial (in Los Angeles): How to optimize intervention potency?




*Barber fidelity*  
*Patron acceptance*




Pharmacists?

*Non-  
Adherence*



**Better medical  
treatment**



*Physician  
inertia*

ORIGINAL ARTICLE

# A Cluster-Randomized Trial of Blood-Pressure Reduction in Black Barbershops

Ronald G. Victor, M.D., Kathleen Lynch, Pharm.D., Ning Li, Ph.D.,  
Ciantel Blyler, Pharm.D., Eric Muhammad, B.A., Joel Handler, M.D.,  
Jeffrey Brettler, M.D., Mohamad Rashid, M.B., Ch.B., Brent Hsu, B.S.,  
Davontae Foxx-Drew, B.A., Norma Moy, B.A., Anthony E. Reid, M.D.,\*  
and Robert M. Elashoff, Ph.D.

# Community Advisory Board



Brian Davis, Ron Victor MD, Tony Reid MD,  
Robert Elashoff PhD, James Smith,  
Stanley White, Luther Sherman

**40 Barbershops randomized**  
(500 patrons)

```
graph TD; A([40 Barbershops randomized<br/>(500 patrons)]) --> B[Baseline<br/>20 barbershops<br/>15 patrons/shop]; A --> C[Baseline<br/>20 barbershops<br/>15 patrons/shop]; B --> D[Enhanced Intervention<br/>Barber-pharmacist BP mgt.]; C --> E[Active Comparator<br/>Barber health educator]; D --> F[6 Month Follow up]; E --> G[6 Month Follow up]; F --> H[Extension Study]; G --> I[Extension Study]; H --> J[12 Month Follow up]; I --> K[12 Month Follow up];
```

**Baseline**

20 barbershops  
15 patrons/shop

**Enhanced Intervention**

Barber-pharmacist BP mgt.

**6 Month Follow up**

**Extension Study**

**12 Month Follow up**

**Baseline**

20 barbershops  
15 patrons/shop

**Active Comparator**

Barber health educator

**6 Month Follow up**

**Extension Study**

**12 Month Follow up**

# Role Model Poster

## Health...It's A Family Affair



I am 45. I have always made sure my daughters go to the doctor but didn't make time to get a doctor for myself. I've been too busy working and providing for my family. I wasn't feeling well for a couple of months and finally let my daughter take me to the emergency room. They prescribed medication for hypertension, diabetes and cholesterol but didn't get me an appointment to follow up with a doctor. Mrs. Byrd did. She got me my own doctor within a week. I feel that I was treated well and will work with the doctor and do what it takes to get my blood pressure, diabetes and cholesterol under control. I want to be there for my children for a very long time.

# Enhanced Intervention



Barber's Blood Pressure  
Work Station




Wireless transmission

**The LA Barbershop  
Blood Pressure  
Study**



Cohort member card with barcode



Pharmacist visits



**Table 1. Baseline Characteristics of the Barbershops and Trial Participants.\***

Characteristic	Intervention Group	Control Group
<b>Barbershops</b>		
No. of barbershops	28	24
Years in business	17.3±14.2	18.1±8.3
No. of barbers per shop	4±2	4±2
<b>Participants</b>		
No. of participants	132	171
Age — yr	54.4±10.2	54.6±9.5
Married or living with a partner — no./total no. (%)	61/131 (46.6)	86/171 (50.3)
Highest educational level — no./total no. (%)		
Not a high school graduate	6/131 (4.6)	13/171 (7.6)
High school graduate or GED equivalent	30/131 (22.9)	49/171 (28.7)
Some college or associate's degree	67/131 (51.1)	76/171 (44.4)
Bachelor's degree	21/131 (16.0)	23/171 (13.5)
Graduate or professional degree	7/131 (5.3)	10/171 (5.8)

## Annual household income — no./total no. (%)

\$0–\$15,999	31/123 (25.2)	34/168 (20.2)
\$16,000–\$24,999	20/123 (16.3)	15/168 (8.9)
\$25,000–\$39,999	9/123 (7.3)	19/168 (11.3)
\$40,000–\$49,999	14/123 (11.4)	21/168 (12.5)
\$50,000–\$74,999	20/123 (16.3)	34/168 (20.2)
\$75,000–\$99,999	16/123 (13.0)	21/168 (12.5)
≥\$100,000	13/123 (10.6)	24/168 (14.3)

## Regular medical care provider — no./total no. (%)

101/131 (77.1) 134/170 (78.8)

## Any health insurance — no. (%)

112 (84.8) 150 (87.7)

## Barbershop patronage

Duration of patronage — yr	10.2±9.6	11.5±9.0
Frequency of visits — every no. of wk	2.0±0.9	2.1±1.1

## Cardiovascular risk factors†

Body-mass index‡	30.8±5.4	31.2±6.0
Current smoker — no./total no. (%)	43/130 (33.1)	51/171 (29.8)
Diabetes — no. (%)	28 (21.2)	38 (22.2)
High cholesterol level — no. (%)	46 (34.8)	41 (24.0)

**Table 2. Primary and Secondary Blood-Pressure Outcomes.\***

Outcome	Intervention Group (N = 132)	Control Group (N = 171)	Intervention Effect	P Value†
<b>Blood pressure</b>				
Systolic blood pressure — mm Hg‡				
At baseline	152.8±10.3	154.6±12.0		
At 6 mo	125.8±11.0	145.4±15.2		
Change	-27.0±13.7	-9.3±16.0	-21.6 (-28.4 to -14.7)§	<0.001
Diastolic blood pressure — mm Hg				
At baseline	92.2±11.5	89.8±11.2		
At 6 mo	74.7±8.3	85.5±12.0		
Change	-17.5±11.0	-4.3±11.8	-14.9 (-19.6 to -10.3)§	<0.001
<b>Hypertension control at 6 mo — no. (%)</b>				
Blood pressure <140/90 mm Hg	118 (89.4)	55 (32.2)	3.4 (2.5 to 4.6)¶	<0.001
Blood pressure <135/85 mm Hg	109 (82.6)	32 (18.7)	5.5 (2.6 to 11.7)¶	<0.001
Blood pressure <130/80 mm Hg	84 (63.6)	20 (11.7)	5.7 (2.5 to 12.8)¶	<0.001

**Table 3. Blood-Pressure Medications at 6 Months.\***

Variable	Intervention Group (N = 132)	Control Group (N = 171)	Mean Difference or Relative Risk (95% CI) <sup>†</sup>	P Value <sup>‡</sup>
Mean no. of blood-pressure medications per participant	2.6±0.9	1.4±1.4	1.9 (1.3–2.4)	<0.001
Drug class				
First-line drugs — no. (%)				
ACE inhibitor or ARB	130 (98.5)	71 (41.5)	2.4 (2.0–2.8)	<0.001
Calcium-channel blocker	125 (94.7)	56 (32.7)	3.0 (2.4–3.6)	<0.001
Diuretic	61 (46.2)	49 (28.7)	1.6 (1.3–2.1)	<0.001
Add-on drugs — no. (%)				
Aldosterone antagonist	14 (10.6)	2 (1.2)	7.0 (2.5–19.2)	<0.001
Beta-blocker	14 (10.6)	33 (19.3)	0.5 (0.3–0.8)	0.008

\* Plus-minus values are means ±SD. ACE denotes angiotensin-converting enzyme, and ARB angiotensin-receptor blocker.

<sup>†</sup> Mean difference is shown for number of blood-pressure medications per participant, and relative risk is shown for drug class.

<sup>‡</sup> For number of blood-pressure medications per participant, the P value was calculated from linear mixed-effects models with random intercepts for clusters. For drug class, P values were calculated from generalized estimating equations with a compound symmetry working correlation to account for cluster effects. For all P values, the estimated between-group difference was controlled for baseline systolic blood pressure, routine doctor, and high cholesterol level.



# Outline

- Quality and safety gaps in healthcare
- Comprehensive medication management (CMM)
  - Definition and comparison to MTM
  - Final results from USC CMMI HCIA
- CMM at local, state, and national levels
- Next steps

# Business Case for Spread and Sustainment of Advanced Practice Pharmacist Programs

- **Cost savings / ROI:** Reduction in acute care utilization for high-risk populations (e.g., Whole Person Care)
- **Direct billing:** LA County Dept of Mental Health (85% of physician payment rate)
- **Gain sharing / P4P**
- **340B program**
- **Medicare Quality Payment Program:** <https://qpp.cms.gov/>
- **Traditional fee-for-service billing:** Incident-to +/- hospital fee or POC testing, diabetes self-management, chronic care management, care transitions, Annual Medicare Wellness visits



# Project Overview:

## The California Right Meds Collaborative

- A **comprehensive medication management (CMM) collaborative** for the state of **California**, initially focusing on key counties as well as **Cook County in Chicago** that will advance the ability of community pharmacists to provide high-impact services for underserved populations
- An ongoing source of **best practices, tools, resources, support, coaching, and expertise** that will ensure the success of CMM programs in improving health outcomes while lowering costs for the most challenging high-risk underserved patients in alignment with health system priorities

# **The California Right Meds Collaborative**


- Based on HRSA Patient Safety and Clinical Pharmacy Services Collaborative
  - IHI Breakthrough Learning Series
- Finalize Change Package and Workbook
- Host 2 launch webinars to generate interest and enrollment in select areas
- First live meeting targeted for June 2018 (Q 6 months)
- Monthly webinars
- Develop pool of regional coaches
- Funding: Mix of external funding and modest membership dues (CE-level) from participants

# Top 10 Potentially Preventable Readmissions

APR DRG Number	Medical APR DRG Description
194	Heart Failure
140	Chronic Obstructive Lung Disease
750	Schizophrenia
139	Other Pneumonia
751	Major Depressive Disorder
198	Angina Pectoris and Coronary Atherosclerosis
753	Bipolar Disorders
720	Septicemia and Disseminated Infection
460	Renal Failure
201	Cardia Arrhythmia and Conduction Disturbance

All Patients Refined Diagnosis Related Groups (**APR DRG**) is a classification system that classifies patients according to their reason of admission, severity of illness and risk of mortality

# Whole Person Care, Health Homes Section 2703



# LA County High Risk Patient / Mental Health Collaboration



- 14 FTE
- CMM- psych & related comorbidities
- Refill Drop-In/Bridge Services (missed appointment)
- Opioid management / prevention services (Buprenorphine/Naltrexone, etc,)
- LAI Induction Services
- Clozapine Medication Group
- Transitions of Care



- Whole Person Care (CMS 1115 Waiver) program for LA County (population 10 million, 4 million Medicaid)
- 100,000 targeted patients (2.5% of all Medicaid) for transitional support services
- 8 FTE allocated to Regional Coordinating Centers
- 4-5 FTE allocated to jail transition




- Program strategy and co-management
- Tie resources together between the university and the county (e.g., data analytics, pharmacoeconomic analyses, precision medicine, students)

# ACHIEVING EXCELLENCE IN PHARMACEUTICAL CARE

## A STRATEGY FOR SCOTLAND



IMPROVED AND  
INCREASED USE OF  
**COMMUNITY  
PHARMACY SERVICES**



PHARMACY TEAMS  
**INTEGRATED INTO  
GP PRACTICES**



TRANSFORMED  
**HOSPITAL PHARMACY  
SERVICES**



PHARMACEUTICAL CARE  
THAT SUPPORTS  
**SAFER USE OF  
MEDICINES**



IMPROVED  
PHARMACEUTICAL CARE  
**AT HOME OR IN A  
CARE HOME**



ENHANCED ACCESS TO  
PHARMACEUTICAL CARE IN  
**REMOTE AND RURAL  
COMMUNITIES**



PHARMACY WORKFORCE  
WITH **ENHANCED  
CLINICAL CAPABILITY  
AND CAPACITY**



IMPROVED SERVICE  
DELIVERY THROUGH  
**DIGITAL INFORMATION  
AND TECHNOLOGIES**



**SUSTAINABLE  
SERVICES** THAT MEET  
POPULATION NEEDS

INDIVIDUALIZED CARE

<http://pharmweb.usc.edu/MedicationManagement/>